KRSA

36.9854.33%
JV

Jonathan Violin

Independent Director

Dr. Jonathan Violin, Ph.D & MBA., is President & CEO of Korsana Biosciences, Inc. since 2025 and is its Director & Secretary. Dr. Violin was Interim Chief Executive Officer of Crescent Biopharma, Inc. until April 2025 and serves as its Director since October 2024. He Founded at Quellis Biosciences, Inc and served as Chief Executive Officer and Director since January 2021 and was its Treasurer and Secretary from December 2018 until the Quellis Acquisition and served as President of Quellis from December 2018 to December 2020. Dr. Violin also served as a consultant for Quellis from December 2017 to April 2021. He served as Manager and Chief Executive Officer at Viridian, LLC. He served as an Independent Director at Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.) since January 28, 2021 until January 23, 2026. He was a Co-Founder of Viridian Therapeutics, Inc. since 2020. He served as Chief Executive Officer and Director at Viridian Therapeutics, Inc since January 15, 2021 until February 6, 2023. He served as President at Viridian Therapeutics, Inc. since October 2020 until February 6, 2023. He served as Senior Vice President of Scientific Affairs and Investor Relations Officer at Trevena, Inc., from January 2018 to November 2018. He served as its Chief Operating Officer at Viridian Therapeutics, Inc since October 2020 until January 15, 2021. Prior to that, Dr. Violin co-founded Dianthus Therapeutics, Inc., a biotechnology company, in May 2019. Dr. Violin was Vice President of Corporate Strategy & Investor Relations at Trevena, Inc., until 2018. Dr. Violin served as the Senior Director of Investor Relations at Trevena, Inc. since January 2016 and serves as its Scientific Co-Founder. Dr. Violin served as Director of Investor Relations at Trevena, Inc. from April 2014 to January 2016. Dr. Violin served as the Head of Biology at Trevena, Inc., since January 2010. Dr. Violin joined Trevena as a Research Scientist. Prior to this, he was a post-doctoral fellow in the laboratory of Dr. Robert Lefkowitz at Duke University Medical Center, where he studied biased ligands and beta-arrest in functions for a variety of GPCR. His research helped establish how biased ligands elicit unique cellular pharmacology with potential to translate into differentiated therapeutics. Dr. Violin holds a Ph.D. from the Pharmacology at the University of California, San Diego, where he developed biosensors to study the spatial and temporal dynamics of kinase signaling. He also received an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business and a B.S. in Chemical Pharmacology from Duke University.

Positions